Orforglipron is an oral non-peptide GLP-1 pill, so its dosing involves no reconstitution or insulin-syringe math. The mg figures here trace to published trials rather than serving as a substitute for the current label. Phase 2 obesity tested once-daily 12, 24, 36, and 45 mg; Phase 3 obesity (ATTAIN-1) used 6, 12, and 36 mg; Phase 3 diabetes (ACHIEVE-1) used 3, 12, and 36 mg.[1][2][3]
Reviewed for accuracy · Last reviewed July 8, 2026Because it is an oral tablet, orforglipron has no reconstitution or syringe math. Trials used once-daily oral doses reached through gradual escalation. The doses below describe what was studied, not a substitute for the current prescribing label:
Each program reached its target dose through staged escalation, stepping up over several weeks so the gut can adjust, which is how the trials aimed to keep gastrointestinal effects tolerable. Treat these numbers as a description of what was studied; for real use, follow the current product label and a prescriber.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting or adjusting any compound.